| Author | dc.contributor.author | Sabugo Siraqyan, María Francisca | |
| Author | dc.contributor.author | Liberman Guendelman, Claudio | es_CL |
| Author | dc.contributor.author | Niedmann, Juan Pablo | es_CL |
| Author | dc.contributor.author | Soto Sáez, Lilian | es_CL |
| Author | dc.contributor.author | Cuchacovich Turteltaub, Miguel | es_CL |
| Admission date | dc.date.accessioned | 2010-01-22T12:21:40Z | |
| Available date | dc.date.available | 2010-01-22T12:21:40Z | |
| Publication date | dc.date.issued | 2008-04 | |
| Cita de ítem | dc.identifier.citation | CLINICAL RHEUMATOLOGY Volume: 27 Issue: 4 Pages: 533-535 Published: APR 2008 | en_US |
| Identifier | dc.identifier.issn | 0770-3198 | |
| Identifier | dc.identifier.other | 10.1007/s10067-007-0767-y | |
| Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/128283 | |
| Abstract | dc.description.abstract | SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis-osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-alpha) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-alpha blockade therapy. | en_US |
| Lenguage | dc.language.iso | en | en_US |
| Publisher | dc.publisher | SPRINGER | en_US |
| Keywords | dc.subject | NECROSIS-FACTOR-ALPHA | en_US |
| Título | dc.title | Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism | en_US |
| Document type | dc.type | Artículo de revista | |
